Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma.

Villanueva A, Llovet JM.

Hepatology. 2012 Dec;56(6):2416-9. doi: 10.1002/hep.26124. No abstract available.

PMID:
23212778
2.

Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma.

Feng YH, Lin CY, Huang WT, Wu CL, Fang JL, Tsao CJ.

Med Oncol. 2011 Dec;28(4):1080-8. doi: 10.1007/s12032-010-9650-9. Epub 2010 Aug 24.

PMID:
20734163
3.

Hepatocellular carcinoma: molecular and genomic guideline for the clinician.

Frenette C, Gish RG.

Clin Liver Dis. 2011 May;15(2):307-21, vii-x. doi: 10.1016/j.cld.2011.03.010. Review.

PMID:
21689615
4.

Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma.

Boucher E, Garin E, Guylligomarc'h A, Olivié D, Boudjema K, Raoul JL.

Radiother Oncol. 2007 Jan;82(1):76-82. Epub 2006 Dec 4.

PMID:
17141900
5.

Hepatocellular carcinoma presenting with bone metastasis.

Melichar B, Voboril Z, Toupková M, Dvorák J.

J Exp Clin Cancer Res. 2002 Sep;21(3):433-6.

PMID:
12385591
6.

Gastric radiation enteritis after intra-arterial yttrium-90 microsphere therapy for early stage hepatocellular carcinoma.

Aloia TA, Barakat O, Connelly J, Haykal N, Michel D, Gaber AO, Ghobrial RM.

Exp Clin Transplant. 2009 Sep;7(3):141-4.

7.

[Chemotherapy].

Ikeda M, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Okusaka T.

Gan To Kagaku Ryoho. 2010 Mar;37(3):408-12. Review. Japanese.

PMID:
20332676
8.

Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies.

Marquardt JU, Galle PR, Teufel A.

J Hepatol. 2012 Jan;56(1):267-75. doi: 10.1016/j.jhep.2011.07.007. Epub 2011 Jul 23. Review.

9.
10.

[Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].

Zhou Q, Shi Y, Chen J, Liu B, Wang Y, Zhu D, Zhang HT, Xu P, Gong Y, Chen G, Wei S, Qiu X, Niu Z, Chen X, Lei Z, Duan L, Wu Z.

Zhongguo Fei Ai Za Zhi. 2011 Feb;14(2):86-106. doi: 10.3779/j.issn.1009-3419.2011.02.15. Chinese. Erratum in: Zhongguo Fei Ai Za Zhi. 2011 Jul 20;14(7):592.

11.

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, Mazzaferro V.

J Hepatol. 2010 May;52(5):771-5. doi: 10.1016/j.jhep.2010.01.025. Epub 2010 Mar 4.

12.

New drugs for the treatment of hepatocellular carcinoma.

Boucher E, Forner A, Reig M, Bruix J.

Liver Int. 2009 Jan;29 Suppl 1:148-58. doi: 10.1111/j.1478-3231.2008.01929.x. Review.

PMID:
19207980
13.

[Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma].

Nagasue N, Yukaya H, Okamura J, Kuroda C, Kubo Y, Hirai K, Tanikawa K, Okita K, Ando K, Tamura K.

Gan To Kagaku Ryoho. 1986 Sep;13(9):2786-92. Japanese.

PMID:
3019251
14.

Aggressive multimodality treatment for intra-hepatic recurrence of hepatocellular carcinoma following hepatic resection.

Chan KM, Lee WC, Hung CF, Yu MC, Jan YY, Chen MF.

Chang Gung Med J. 2005 Aug;28(8):543-50.

15.

[Hepatocellular carcinoma in undamaged liver].

Feketé F, Belghiti J, Flejou JF, Panis Y, Molas G.

Ann Ital Chir. 1991 Nov-Dec;62(6):545-9; discussion 549-50. Italian.

PMID:
1667890
16.

[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma].

Nakazaki H, Kuramoto S, Watanabe M, Maeda T, Hanawa S, Hasebe Y, Suzuki Y, Yanagita K, Yoshio T.

Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1501-3. Japanese.

PMID:
1326917
17.

Rationale for clinical trials of coagulation: reactive drugs in hepatocellular carcinoma.

Zacharski LR, Hommann M, Kaufmann R.

Expert Rev Cardiovasc Ther. 2004 Sep;2(5):777-84. Review.

PMID:
15350179
18.

Future of molecular profiling of human hepatocellular carcinoma.

Roessler S, Budhu A, Wang XW.

Future Oncol. 2007 Aug;3(4):429-39. Review.

PMID:
17661718
19.

High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis.

Giménez-Barcons M, Franco S, Suárez Y, Forns X, Ampurdanès S, Puig-Basagoiti F, Sánchez-Fueyo A, Barrera JM, Llovet JM, Bruix J, Sánchez-Tapias JM, Rodés J, Saiz JC.

Hepatology. 2001 Jul;34(1):158-67.

PMID:
11431747
20.

Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma.

Emile JF, Lemoine A, Azoulay D, Debuire B, Bismuth H, Reynès M.

Histopathology. 2001 Mar;38(3):225-31.

PMID:
11260303

Supplemental Content

Support Center